Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

1. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. (PubMed)

Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Guideline-recommended doses of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and β blockers are similar for men and women with heart failure with reduced ejection fraction (HFrEF), even though there are known sex differences in pharmacokinetics of these drugs. We hypothesised that there might be sex differences in the optimal (...) dose of ACE inhibitors or ARBs and β blockers in patients with HFrEF.We did a post-hoc analysis of BIOSTAT-CHF, a prospective study in 11 European countries of patients with heart failure in whom initiation and up-titration of ACE inhibitors or ARBs and β blockers was encouraged by protocol. We included only patients with left ventricular ejection fraction less than 40%, and excluded those who died within the first 3 months. Primary outcome was a composite of time to all-cause mortality

2019 Lancet

2. Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness

Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness Last updated: May 15, 2019 Project Number: RC1119-000 Product Line: Research Type: Drug (...) Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of ivabradine for patients with stable chronic heart failure and with left ventricular ejection fraction > 35% and 40%? Key Message There were no studies identified with inclusion criteria of patients with stable chronic heart failure and left ventricular ejection fraction greater than 35% and less than or equal to 40% Two studies, however, included patients with LVEF less than 40% and were

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines

Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness (...) , and Guidelines Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines Last updated: August 19, 2019 Project Number: RC1163-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and clinical utility of natriuretic peptide testing for the monitoring of heart failure therapy? What is the cost

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness

Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness | CADTH.ca Find the information you need Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments (...) : Clinical Utility and Cost-Effectiveness Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness Last updated: August 27, 2019 Project Number: RB1380-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of point of care ultrasound for the assessment of patients with suspected or known chronic heart failure

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness

Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness | CADTH.ca Find the information you need Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: Clinical Effectiveness Last updated: March 19, 2019 Project Number: RB1316-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type (...) : Report Question What is the clinical effectiveness of ivabradine for patients with stable chronic heart failure? Key Message Two randomized controlled trials regarding the clinical effectiveness of ivabradine for patients with stable chronic heart failure were identified. Files Rapid Response Summary of Abstracts Published : March 19, 2019 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure

Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure 1 Translation of the key statement of the final report N16-02 Telemonitoring mithilfe von aktiven kardialen implantierbaren Aggregaten bei ventrikulärer Tachyarrhythmie sowie Herzinsuffizienz (Version 1.2; Status: 4 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German (...) original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. N16-02 Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure 1 Extract of final report N16-02 Version 1.2 Telemonitoring using active cardiac implantable devices 4 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Telemonitoring using

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

7. Ivabradine (Lancora) for Heart Failure

Ivabradine (Lancora) for Heart Failure Ivabradine (Lancora) for Heart Failure | CADTH.ca Find the information you need Ivabradine (Lancora) for Heart Failure Ivabradine (Lancora) for Heart Failure Last updated: August 8, 2019 Project Number: HO0006-000 Product Line: Technology Review Result type: Report Heart failure is a condition characterized by reduced cardiac output occurring due to complications of cardiovascular disease. It is a leading cause of hospital admissions and has a poor

2019 Publication 4890897

8. Cardiac rehabilitation for heart failure can improve quality of life and fitness. (PubMed)

Cardiac rehabilitation for heart failure can improve quality of life and fitness. The studyTaylor RS, Walker S, Ciani O, et al. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis. Health Technol Assess 2019;23:1-98.This project was funded by the NIHR Health Technology Assessment Programme (project number 15/80/30).To read the full NIHR Signal, go to https://discover.dc.nihr.ac.uk/content/signal-000803/cardiac (...) -rehabilitation-for-heart-failure-can-improve-quality-of-life-and-fitness.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

2019 BMJ

9. Patients Hospitalized with Heart Failure: Risk Assessment, Management, and Clinical Trajectory

Patients Hospitalized with Heart Failure: Risk Assessment, Management, and Clinical Trajectory EXPERT CONSENSUS DECISION PATHWAY 2019 ACC Expert Consensus Decision PathwayonRiskAssessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure A Report of the American College of Cardiology Solution Set Oversight Committee Writing Committee Steven M. Hollenberg, MD, FACC, Chair Lynne Warner Stevenson, MD, FACC, Vice Chair Tariq Ahmad, MD, MPH, FACC Vaibhav J. Amin, MD (...) ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure ... - APPENDIX 2 Peer Reviewer Relationships With Industry and Other Entities—2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and ClinicalTrajectoryofPatientsHospitalizedWithHeart Failure .. ... - APPENDIX 3 Abbreviations ... ... - APPENDIX 4 Advance Care Planning .. ... - APPENDIX 5 Alternative Format for the Focused Discharge Handoff

2019 American College of Cardiology

10. The Effect of Renal Denervation on Exercise Tolerance in Patients with Heart Failure

The Effect of Renal Denervation on Exercise Tolerance in Patients with Heart Failure "The Effect of Renal Denervation on Exercise Tolerance in Patients with" by Meredith Dahle < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Heart Failure is a growing clinical syndrome that results in major impacts on patients and the medical system. Previously, therapy has (...) improved symptoms while leaving the patient disabled in the later stages. Renal denervation (RDN) is a procedure that is being researched for its effect on improving the condition of heart failure along with its symptoms and increasing exercise tolerance in patients. Methods: Exhaustive search of available medical literature using MEDLINE via PubMed, CINAHL, Web of Science and Google Scholar using the keywords renal denervation, heart failure and exercise tolerance. The studies that fit the eligibility

2019 Pacific University EBM Capstone Project

11. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. (PubMed)

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.In this phase 3, placebo (...) -controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death.Over a median of 18.2 months, the primary outcome occurred

2019 NEJM

12. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. (PubMed)

Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. In patients with heart failure and reduced ejection fraction (HFrEF), treatment with sacubitril-valsartan reduces N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations. The effect of sacubitril-valsartan on cardiac remodeling is uncertain.To determine whether NT

2019 JAMA

13. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. (PubMed)

Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. Compared with enalapril, sacubitril-valsartan reduces cardiovascular mortality and heart failure hospitalization in patients with heart failure and reduced ejection fraction (HFrEF). These benefits may be related to effects on hemodynamics and cardiac remodeling.To determine whether treatment of HFrEF with sacubitril-valsartan improves (...) central aortic stiffness and cardiac remodeling compared with enalapril.Randomized, double-blind clinical trial of 464 participants with heart failure and ejection fraction of 40% or less enrolled across 85 US sites between August 17, 2016, and June 28, 2018. Follow-up was completed on January 26, 2019.Randomization (1:1) to sacubitril-valsartan (n = 231; target dosage, 97/103 mg twice daily) vs enalapril (n = 233; target dosage, 10 mg twice daily) for 12 weeks.The primary outcome was change from

2019 JAMA

14. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease

Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease Patients with chronic coronary artery disease or peripheral artery disease and history of heart failure (HF) are at high risk for major adverse cardiovascular events. We explored the effects of rivaroxaban with or without aspirin in these patients.The COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) randomized 27 395 participants with chronic (...) coronary artery disease or peripheral artery disease to rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily, rivaroxaban 5 mg twice daily alone, or aspirin 100 mg alone. Patients with New York Heart Association functional class III or IV HF or left ventricular ejection fraction (EF) <30% were excluded. The primary major adverse cardiovascular events outcome comprised cardiovascular death, stroke, or myocardial infarction, and the primary safety outcome was major bleeding using modified

2019 EvidenceUpdates

15. Hand-held ultrasound devices for cardiac assessment and diagnosis of heart failure, in the community or primary care setting

Hand-held ultrasound devices for cardiac assessment and diagnosis of heart failure, in the community or primary care setting Hand-held ultrasound devices - Health Technology Wales > Hand-held ultrasound devices Hand-held ultrasound devices Topic Status Complete Hand-held ultrasound devices for cardiac assessment and diagnosis of heart failure, in the community or primary care setting. Outcome of the appraisal Hand-held ultrasound devices (HUDs) show promise in the diagnosis of heart failure (...) in a primary care or community setting, but the current evidence is insufficient to support routine adoption. HUDs have the potential to reduce secondary care referrals if heart failure is excluded and to facilitate earlier treatment if confirmed, but convincing evidence is needed to substantiate any clinical and system benefits. HTW recommends further research to investigate the benefits of implementing HUDs in a primary care or community setting in Wales; see Guidance for more information. Why

2019 Health Technology Wales

16. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. (PubMed)

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear.We randomly assigned 4822 patients with New York Heart (...) Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening

2019 NEJM

17. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. (PubMed)

Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. To investigate the cardiovascular effectiveness of sodium glucose cotransporter 2 (SGLT2) inhibitors in routine clinical practice.Cohort study using data from nationwide registers and an active-comparator new-user design.Denmark, Norway, and Sweden, from April 2013 to December 2016.20 983 new users of SGLT2 inhibitors and 20 983 new users (...) of dipeptidyl peptidase 4 (DPP4) inhibitors, aged 35-84, matched by age, sex, history of major cardiovascular disease, and propensity score.Primary outcomes were major cardiovascular events (composite of myocardial infarction, stroke, and cardiovascular death) and heart failure (hospital admission for heart failure or death due to heart failure). Secondary outcomes were the individual components of the cardiovascular composite and any cause death. In the primary analyses, patients were defined as exposed

2019 BMJ

18. Effects of Serelaxin in Patients with Acute Heart Failure. (PubMed)

Effects of Serelaxin in Patients with Acute Heart Failure. Serelaxin is a recombinant form of human relaxin-2, a vasodilator hormone that contributes to cardiovascular and renal adaptations during pregnancy. Previous studies have suggested that treatment with serelaxin may result in relief of symptoms and in better outcomes in patients with acute heart failure.In this multicenter, double-blind, placebo-controlled, event-driven trial, we enrolled patients who were hospitalized for acute heart (...) and worsening heart failure at 5 days.A total of 6545 patients were included in the intention-to-treat analysis. At day 180, death from cardiovascular causes had occurred in 285 of the 3274 patients (8.7%) in the serelaxin group and in 290 of the 3271 patients (8.9%) in the placebo group (hazard ratio, 0.98; 95% confidence interval [CI], 0.83 to 1.15; P = 0.77). At day 5, worsening heart failure had occurred in 227 patients (6.9%) in the serelaxin group and in 252 (7.7%) in the placebo group (hazard ratio

2019 NEJM

19. Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction

Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction Angiotensin-converting enzyme (ACE) inhibitors are beneficial in heart failure with reduced ejection fraction (HFrEF). We sought to describe longitudinal trends in estimated glomerular filtration rate (eGFR) in HFrEF and how ACE-inhibitor therapy influences these changes.Post hoc analysis of trial data.Symptomatic (Treatment Trial, n=2,423) and asymptomatic (Prevention

2019 EvidenceUpdates

20. Hand-held ultrasound devices for cardiac assessment and diagnosis of heart failure

Hand-held ultrasound devices for cardiac assessment and diagnosis of heart failure Hand-held ultrasound devices - Health Technology Wales > Hand-held ultrasound devices Hand-held ultrasound devices Topic Status Complete Hand-held ultrasound devices for cardiac assessment and diagnosis of heart failure, in the community or primary care setting. Outcome of the appraisal Hand-held ultrasound devices (HUDs) show promise in the diagnosis of heart failure in a primary care or community setting (...) , but the current evidence is insufficient to support routine adoption. HUDs have the potential to reduce secondary care referrals if heart failure is excluded and to facilitate earlier treatment if confirmed, but convincing evidence is needed to substantiate any clinical and system benefits. HTW recommends further research to investigate the benefits of implementing HUDs in a primary care or community setting in Wales; see Guidance for more information. Why was this topic appraised? Heart failure is a common

2019 Health Technology Wales